Media Coverage
15 Fastest-Growing Private Life Science Companies in the U.S.
Inc. magazine collates an annual list of the fastest-growing private companies in America. This year, 15 of the top 5,000 were related to healthcare, medical…
Bioasis and BioAgilytix Announce Strategic Collaboration to Advance xb3 TM-001 in Brain Cancer
Bioasis Technologies and testing services provider BioAgilytix will partner on the development and validation of bioanalytical methods to support and advance the xB3 -001 program,…
BioAgilytix and ATCC Present the First ‘Trends in Cell-Based Assays’ Forum
The first ‘Trends in Cell-Based Assays’ forum was held this week in Cambridge, hosted by ATCC and BioAgilytix, who partnered with Shire Pharmaceuticals, Takeda Pharmaceuticals,…
Clinical Relevance of Immunogenicity: an Interview with Arno Kromminga
Dr. Arno Kromminga is a certified specialized immunologist with over 20 years of expertise covering the entire cascade of assay strategy and characterization of immune…
Exploratory Biomarker Testing: to Qualify or Validate the Assay?
There is a lot of confusion in the world of biomarker testing when it comes to the terms ‘assay qualification’ and ‘assay validation’. These two…
Immunogenicity Considerations for ADCs: A Focus on Neutralizing Antibody Assays
Summary With increasing numbers of ADCs in clinical trials and post-marketing surveillance, more clinical data are being collected that will increase our understanding of ADCs,…
ATCC Adds Novel In Vitro Model to Expanding Portfolio
ATCC has released an in vitro model system for a key mechanism of invasion and metastasis in lung cancer as the company continues its efforts…
Bioanalysis Zone’s “Ask the Experts” Series on Biosimilars
Summary Biosimilars are subsequent versions of an innovator product and have gained popularity over the last 30 years. This series explores the role of biosimilars,…
Triangle Business Journal: Durham’s BioAgilytix heading into expansion mode
BioAgilytix is beefing up in Durham. The contact research organization is expanding its existing 29,000-square-foot space to roughly 50,000 square feet at 2300 Englert Drive…
Meeting the Rigorous Demands of Biosimilar Pharmacokinetics
Abstract Rapid growth of the market for biosimilar products is expected in the next few years, as the patents for a large number of approved…